March 20, 2020
 

Cantel continues to monitor updates from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes the disease now called Coronavirus Disease 2019 (COVID-19). On March 11, 2020 the WHO officially declared the outbreak as a global pandemic, acknowledging the virus will likely spread to all countries on the globe.

 

Due to the novel nature of the virus, no official methods exist to test the efficacy of a disinfectant against the enveloped virus, SARS-CoV-2. These procedures take a significant amount of time to develop, validate, and standardize. In the meantime, disinfectant manufacturers, care givers, environmental health and safety workers, and patients must rely on updates from groups like the EPA, CDC and WHO to ensure they are executing the most relevant procedures to protect against the spread of this highly infectious agent.

 

In the absence of a validated test, Cantel has taken steps to understand SARS-CoV-2 and the efficacy of our high-level disinfectants (HLDs) and sterilants against it. Confirmatory testing performed by a third-party laboratory has verified the efficacy of Cantel’s Cold Sterilants (MinncareTM and RenalinTM 100) on hard, non-porous surfaces by demonstrating a complete inactivation of the 229E human coronavirus strain in 5 minutes at room temperature when diluted for use according to label instructions1. For more convenient applications, Actril™ Cold Sterilant delivers the same, reliable active ingredient in a ready-to-use (no dilution needed) version of the same formulation. Additionally, these HLDs/sterilant products carry surface disinfection claims against enveloped viruses similar to coronavirus2 and have shown efficacy on more challenging, non-enveloped viruses3 and many other more ’robust’ pathogens.3,4,5

 

When performing routine surface disinfection using HLDs and sterilants from Cantel, you can rest assured that if used in accordance with their instructions for use and for their indicated purposes, these products have validated efficacy against certain challenging pathogens and will provide high level efficacy in accordance with the products’ published specifications and labeling information.

 

Kristopher Murphy, PhD 
Director of Chemistry – R&D

 

April Doering
Sr Director Microbiology & Sterilization

 
1) Testing by ATS Labs of St. Paul, MN (protocol number MT01042903.COR). A ≥ 4.0 Log reduction of Human coronavirus ATCC
VR-740, strain 229E in the presence of 5% soil on hard, non-porous surfaces using a disinfectant dilution of 1% (1:99). 229E
HCV is a different coronavirus strain than SARS-CoV -2.
2) See product label for product claims and instructions for use against enveloped viruses.
3) W. Bond. Decreasing order of resistance of microorganisms to germicidal chemicals. Regulatory Framework for Disinfectants
and Sterilants. 4th ed. Philadelphia, PA, 1991.
4) Testing by ATS Labs of St. Paul, MN (protocol number MT01051612.MNV). A ≥ 5.64 Log inactivation of Murine Norovirus
Strain MNV-1.CW2 in the presence of 5% soil on hard, non-porous surfaces using Actril™ Cold Sterilant as ready-to-use
5) “Product specifications, indications, contraindications, warnings, precautions and instructions for use can be found in the product labeling supplied with each product.”
 © 2020 Cantel Medical Corp. PCN-00044
 
 

 

 

    COVID-19 Guidance for High Level Surface Disinfectants

     
    March 20, 2020
     

    Cantel continues to monitor updates from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes the disease now called Coronavirus Disease 2019 (COVID-19). On March 11, 2020 the WHO officially declared the outbreak as a global pandemic, acknowledging the virus will likely spread to all countries on the globe.

     

    Due to the novel nature of the virus, no official methods exist to test the efficacy of a disinfectant against the enveloped virus, SARS-CoV-2. These procedures take a significant amount of time to develop, validate, and standardize. In the meantime, disinfectant manufacturers, care givers, environmental health and safety workers, and patients must rely on updates from groups like the EPA, CDC and WHO to ensure they are executing the most relevant procedures to protect against the spread of this highly infectious agent.

     

    In the absence of a validated test, Cantel has taken steps to understand SARS-CoV-2 and the efficacy of our high-level disinfectants (HLDs) and sterilants against it. Confirmatory testing performed by a third-party laboratory has verified the efficacy of Cantel’s Cold Sterilants (MinncareTM and RenalinTM 100) on hard, non-porous surfaces by demonstrating a complete inactivation of the 229E human coronavirus strain in 5 minutes at room temperature when diluted for use according to label instructions1. For more convenient applications, Actril™ Cold Sterilant delivers the same, reliable active ingredient in a ready-to-use (no dilution needed) version of the same formulation. Additionally, these HLDs/sterilant products carry surface disinfection claims against enveloped viruses similar to coronavirus2 and have shown efficacy on more challenging, non-enveloped viruses3 and many other more ’robust’ pathogens.3,4,5

     

    When performing routine surface disinfection using HLDs and sterilants from Cantel, you can rest assured that if used in accordance with their instructions for use and for their indicated purposes, these products have validated efficacy against certain challenging pathogens and will provide high level efficacy in accordance with the products’ published specifications and labeling information.

     

    Kristopher Murphy, PhD 
    Director of Chemistry – R&D

     

    April Doering
    Sr Director Microbiology & Sterilization

     
    1) Testing by ATS Labs of St. Paul, MN (protocol number MT01042903.COR). A ≥ 4.0 Log reduction of Human coronavirus ATCC
    VR-740, strain 229E in the presence of 5% soil on hard, non-porous surfaces using a disinfectant dilution of 1% (1:99). 229E
    HCV is a different coronavirus strain than SARS-CoV -2.
    2) See product label for product claims and instructions for use against enveloped viruses.
    3) W. Bond. Decreasing order of resistance of microorganisms to germicidal chemicals. Regulatory Framework for Disinfectants
    and Sterilants. 4th ed. Philadelphia, PA, 1991.
    4) Testing by ATS Labs of St. Paul, MN (protocol number MT01051612.MNV). A ≥ 5.64 Log inactivation of Murine Norovirus
    Strain MNV-1.CW2 in the presence of 5% soil on hard, non-porous surfaces using Actril™ Cold Sterilant as ready-to-use
    5) “Product specifications, indications, contraindications, warnings, precautions and instructions for use can be found in the product labeling supplied with each product.”
     © 2020 Cantel Medical Corp. PCN-00044
     
     

     

     


Copyright © 2016 Mar Cor Purification. All Rights Reserved.